Malignant melanoma of unknown primary site in patient with pustulosis plantaris Case report

Article Sidebar

PDF


Published: Jun 30, 2014
Keywords:
malignant melanoma, metastasis, vemurafenib, pustulosis plantaris, BRAF inhibitors, lymph node

Main Article Content

Piotr Brzeziński
Head of Military Ambulatory, 6th Military Support Unit, Ustka, Poland
Ahmad Abdulaziz
Assistant of Department of General Surgery, District Hospital, Iława, Poland
Jacek Andruszkiewicz
Assistant of Clinical Department of Surgical Oncology, Prof. Francis Łukaszczyk Oncology Center, Bydgoszcz, Poland
Anca Chiriac
Head of Department of Dermato-Physiology, Apollonia University Iasi, Strada Muzicii nr 2, Iasi Romania

Abstract

We reported a 57 year old woman treated for 2 years because of pustulosis plantaris (periodic exacerbations and remissions). In July 2013 she reported to the Outpatient Surgery because of a tumor in the left groin area. The biopsy revealed: metastases melanomatosis in lymphonodus. The patients was in October at the surgical removal of lymph nodes from left groin area (lymphadenectomy groin - ilio - obturatorii right). Full diagnostic was carried out and searching of of primary foci to no results. In the patient revealed the presence of BRAF and she was qualified to study of drug vemurafenib.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Brzeziński P, Abdulaziz A, Andruszkiewicz J, Chiriac A. Malignant melanoma of unknown primary site in patient with pustulosis plantaris. OncoReview [Internet]. 2014Jun.30 [cited 2024May4];4(2(14):69-1. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/362
Issue
Vol 4 No 2(14) (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Drljevic I, Drljevic K. Dermoscopy of head melanoma-case studies and review of references. Our Dermatol Online 2012; 3: 123-125.
2. Abdulaziz A, Andruszkiewicz J, Brzezinski P. In anticipation of the biopsy. Tumor on the leg. Our Dermatol Online 2014; 5: e1.
3. Kamposioras K, Pentheroudakis G, Pectasides D et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2011; 78: 112-126.
4. Gadiot J, Hooijkaas AI, Deken MA et al. Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther 2013; 6: 1649-58.
5. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20: 315-322